Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Key Points Warren Buffett's company Berkshire Hathaway has never paid a dividend.That hasn't stopped Buffett and his team ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final ...

Alphabet posted strong Q2 results with broad-based growth, resilient Search performance, and an attractive valuation. Learn ...

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.